ConvaTec confirms guidance after strong H1 revenue growth
4th Aug 2022 08:29
(Sharecast News) - ConvaTec reported "strong" revenue growth in its first half on Thursday, up 3.6% on a reported basis to $1.05bn, 8% on a constant currency basis, and 6.4% on an organic basis, with "positive performances" across all of its divisions.
Read moreRBC Capital Markets upgrades Convatec to 'sector perform'
18th May 2022 10:54
(Sharecast News) - Analysts at RBC Capital Markets upgraded medical products and technologies company Convatec from 'underperform' to 'sector perform' on Wednesday, stating further earnings downgrades appeared to be already priced in.
Read moreConvaTec YTD revenues rise amid 'good start' to 2022
12th May 2022 08:52
(Sharecast News) - Medical products and technologies company ConvaTec said on Thursday that group revenues had risen 4.1% in the four months ended 30 April on a constant currency basis as it made "a good start to the year", with solid underlying growth in each of its four categories.
Read moreConvaTec hikes dividend after strong revenue growth
8th Mar 2022 08:22
(Sharecast News) - ConvaTec reported "strong" revenue growth in its annual results on Tuesday, up 7.6% to $2.04bn (£1.56bn), driven by strength in advanced wound care and infusion care and modest growth in ostomy care and continence and critical care.
Read moreConvatec to acquire US-focussed Triad Life Sciences
28th Jan 2022 07:06
(Sharecast News) - Medical solutions firm Convatec has agreed to acquire US-focussed medical device company Triad Life Sciences in a deal worth as much as $275.0m.
Read moreConvatec hires Jonny Mason as next CFO
9th Dec 2021 08:05
(Sharecast News) - ConvaTec has hired former Dixons Carphone finance chief Jonny Mason as to replace Frank Schulkes as chief financial officer.
Read moreConvaTec sees organic revenue growth at upper end of guidance
29th Oct 2021 07:49
(Sharecast News) - Medical products company ConvaTec said on Friday that full-year organic revenue growth is set to be towards the upper end of its guidance range after an in-line third-quarter performance, which saw sales slow from the second quarter.
Read moreJPMorgan upgrades ConvaTec to 'overweight'
9th Sep 2021 09:51
(Sharecast News) - JPMorgan Cazenove upgraded medical products company ConvaTec to 'overweight' from 'neutral' on Thursday, lifting the price target to 272p from 229p as it pointed to an attractive entry point.
Read moreConvaTec confident despite margin pressures
30th Jul 2021 07:29
(Sharecast News) - Medical products company ConvaTec reported "strong" revenue growth ahead of expectations for its first half on Friday, with organic growth at 7.4%, or 7.0% on a constant currency basis to $1.01bn, with growth coming in at 11.0% on a reported basis.
Read moreThursday broker round-up
1st Jul 2021 13:45
(Sharecast News) - Ascential: Berenberg upgrades to buy with a target price of 485p.
Read morePeel Hunt upgrades ConvaTec to 'buy'
6th May 2021 11:13
(Sharecast News) - Peel Hunt upgraded its stance on shares of medical device company ConvaTec on Thursday to 'buy' from 'add' and lifted the price target to 285p from 240p.
Read moreConvatec Q1 revenues grow, maintains FY guidance
29th Apr 2021 10:24
(Sharecast News) - Medical device company Convatec reported improved first-quarter revenues on Thursday but opted to keep its full-year outlook unchanged due to the ongoing Covid-19 pandemic and uncertainties arising from it.
Read moreConvaTec says pandemic created both challenges and opportunities in 2020
5th Mar 2021 07:38
(Sharecast News) - ConvaTec posted a rise in full-year revenue but a dip in earnings after the pandemic created "both challenges and opportunities" for the medical products and technology company in 2020.
Read moreThursday broker round-up
29th Oct 2020 13:18
(Sharecast News) - Morrison: Barclays upgrades to equal weight and keeps target price at 180p.
Read moreConvaTec sees FY revenue growth at top end of guidance
28th Oct 2020 07:50
(Sharecast News) - Medical products company ConvaTec said on Wednesday that it expects to deliver full-year revenue growth at the higher end of guidance following a better-than-expected performance in the third quarter.
Read more